Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice

Surgical Innovation

Volumn 13, Issue 1, 2006, Pages 41-47

  Carter, Joseph J ^a,b   Feingold, Daniel L ^a   Oh, Anthony ^a   Kirman, Irena ^a   Wildbrett, Peer ^a   Stapleton, George ^a   Asi, Zishan ^a   Fowler, Ryan ^a   Bhagat, Govind ^a   Huang, Emina H ^a   Fine, Robert L ^a   Whelan, Richard L ^a  

^a Columbia University ^*  (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Cancer; Flt3 ligand; Immunotherapy; Metastases; Vaccine

Indexed keywords

FLT3 LIGAND; INDIAN INK; PROTEIN TYROSINE KINASE; SODIUM CHLORIDE; TUMOR CELL VACCINE;

ANALYSIS OF VARIANCE; ANESTHESIA INDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER INCIDENCE; CANCER MODEL; CELL COUNT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; EXCISION; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; LAPAROTOMY; LUNG INFILTRATE; LUNG METASTASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PERIOPERATIVE PERIOD; STATISTICAL SIGNIFICANCE; TAIL; TRACHEA; TUMOR CELL; TUMOR GROWTH; VEIN;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; ANIMALS; CANCER VACCINES; FEMALE; LAPAROTOMY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; RANDOM ALLOCATION;

EID: 33744782585     PISSN: 15533506     EISSN: None     Source Type: Journal    
DOI: 10.1177/155335060601300107     Document Type: Article

References (27)

1. Eggermont AM, Steller EP, Marquet RL, et al. Local regional promotion of tumor growth after abdominal surgery is dominant over immuno therapy with interleukin-2 and lymphokine activated killer cells. Cancer Detect Prevent 12:421-29, 1998.
2. Allendorf JD, Bessler M, Horvath KD, et al. Increased tumor establishment and growth after open versus laparoscopic bowel resection in mice. Surg Endosc 12:1035-8, 1998.
3. 2 pneumoperitoneum and the inhibition of this effect with perioperative immunomodulation. Surgical Endoscopy 16:1162-70, 2002.
4. Carter J, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am 10:655-78, 2001.
5. Ordemann J, Jacobi CA, Schwenk W, et al. Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections Surg Endosc 15:600-8, 2001.
6. Trokel MJ, Bessler M, Treat MR, et al. Preservation of immune response after laparoscopy. Surg Endosc 8:1385-8, 1994.
7. Allendorf JD, Bessler M, Whelan RL, et al. Better preservation of immune function after laparoscopic-assisted vs. open bowel resection in a murine model. Dis Colon Rectum 39(suppl):S67-72, 1996.
8. Allendorf JD, Bessler M, Horvath KD, et al. Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. Surg Endosc 13:233-5, 1999.
9. Hammer JH, Nielsen HJ, Moesgaard F, et al. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. Eur Surg Res 24:133-7, 1992.
10. Schuurman B, Heuff G, Beelen RHJ, et al. Enhanced killing capacity of human Kupffer cells after activation with granulocyte/ macrophage-colony-stimulating factor and interferon-γ. Cancer 39:179-84, 1994.
11. Tanemura H, Sakata K, Kunieda T, et al. Influences of operative stress on cell-mediated immunity and on tumor metastasis and their prevention by nonspecific immunotherapy: experimental studies in rats. J Surg Oncol 21:189-95, 1982.
12. Heys SD, Deehan DJ, Eremin O. Interleukin-2 treatment in colorectal cancer: current results and future prospects. Eur J Surg Oncol 20:622-9, 1994.
13. Hill ADK, Redmond HP, Naama HA, et al. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery 119:178-85, 1996.
14. Sabel M, Hill H, Jong Y, et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 130:470-8, 2001.
15. Braun SE. Chen K. Blazar BR, et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10:2141-51, 1999.
16. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/ Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459-64, 1994.
17. Carter JJ, Feingold DL, Wildbrett P, et al: Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with Flt3 ligand in mice. Surg Innova 12:319-326, 2005.
18. Lennard TW, Shenton BK, Borzotta A, et al. The influence of surgical operations on components of the human immune system. Br J Surg 72:771-6, 1985.
19. Nielsen HJ, Pedersen BK, Moesgaard F. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity. Acta Chir Scand 155:377-82, 1989.
20. Christou NV, Superina R, Broadhead M, et al. Postoperative depression of host resistance: determinants and effect of peripheral protein-sparing therapy. Surgery 92:786-92, 1982.
21. Nielsen HJ, Moesgaard F, Kehlet H. Ranitidine for prevention of postoperative suppression of delayed hypersensitivity. Am J Surg 157:291-4, 1989.
22. Hjortso NC, Kehlet H. Influence of surgery, age, and serum albumin on delayed hypersensitivity. Acta Chir Scand 152:175-9, 1986.
23. Mels AK, Statius Muller MG, van Leeuwen PA, et al. Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br J Surg 88:539-44, 2001.
24. Kirman I, Asi I, Carter J, et al. Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 16: 654-8, 2002.
25. Gray BN, Walker C, Andrewartha L, et al. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous turnout cells in large bowel cancer. J Surg Oncol 40:34-7, 1989.
26. Vermorken JB, Claessen AME, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353:345-50, 1999.
27. Hoover HC, Hanna MG. Active immunotherapy in colorectal cancer. Semin Surg Oncol 5:436-40, 1989.